SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Başak A. Nazlı)
 

Sökning: WFRF:(Başak A. Nazlı) > The Effect of SMN G...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004209naa a2200745 4500
001oai:DiVA.org:umu-179430
003SwePub
008210204s2021 | |||||||||||000 ||eng|
024a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1794302 URI
024a https://doi.org/10.1002/ana.260092 DOI
040 a (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
100a Moisse, Matthieu4 aut
2451 0a The Effect of SMN Gene Dosage on ALS Risk and Disease Severity
264 c 2021-01-15
264 1b John Wiley & Sons,c 2021
338 a electronic2 rdacarrier
520 a Objective: The role of the survival of motor neuron (SMN) gene in amyotrophic lateral sclerosis (ALS) is unclear, with several conflicting reports. A decisive result on this topic is needed, given that treatment options are available now for SMN deficiency.Methods: In this largest multicenter case control study to evaluate the effect of SMN1 and SMN2 copy numbers in ALS, we used whole genome sequencing data from Project MinE data freeze 2. SMN copy numbers of 6,375 patients with ALS and 2,412 controls were called from whole genome sequencing data, and the reliability of the calls was tested with multiplex ligation-dependent probe amplification data.Results: The copy number distribution of SMN1 and SMN2 between cases and controls did not show any statistical differences (binomial multivariate logistic regression SMN1 p = 0.54 and SMN2 p = 0.49). In addition, the copy number of SMN did not associate with patient survival (Royston-Parmar; SMN1 p = 0.78 and SMN2 p = 0.23) or age at onset (Royston-Parmar; SMN1 p = 0.75 and SMN2 p = 0.63).Interpretation: In our well-powered study, there was no association of SMN1 or SMN2 copy numbers with the risk of ALS or ALS disease severity. This suggests that changing SMN protein levels in the physiological range may not modify ALS disease course. This is an important finding in the light of emerging therapies targeted at SMN deficiencies.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Neurologi0 (SwePub)302072 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Neurology0 (SwePub)302072 hsv//eng
700a Zwamborn, Ramona A. J.4 aut
700a van Vugt, Joke4 aut
700a van Der Spek, Rick4 aut
700a van Rheenen, Wouter4 aut
700a Kenna, Brendan4 aut
700a Van Eijk, Kristel4 aut
700a Kenna, Kevin4 aut
700a Corcia, Philippe4 aut
700a Couratier, Philippe4 aut
700a Vourc'h, Patrick4 aut
700a Hardiman, Orla4 aut
700a McLaughin, Russell4 aut
700a Gotkine, Marc4 aut
700a Drory, Vivian4 aut
700a Ticozzi, Nicola4 aut
700a Silani, Vincenzo4 aut
700a de Carvalho, Mamede4 aut
700a Mora Pardina, Jesús S.4 aut
700a Povedano, Monica4 aut
700a Andersen, Peter M.,d 1962-u Umeå universitet,Neurovetenskaper4 aut0 (Swepub:umu)pean0001
700a Weber, Markus4 aut
700a Basak, Nazli A.4 aut
700a Chen, Xiao4 aut
700a Eberle, Michael A.4 aut
700a Al-Chalabi, Ammar4 aut
700a Shaw, Chris4 aut
700a Shaw, Pamela J.4 aut
700a Morrison, Karen E.4 aut
700a Landers, John E.4 aut
700a Glass, Jonathan D.4 aut
700a Robberecht, Wim4 aut
700a van Es, Michael4 aut
700a van den Berg, Leonard4 aut
700a Veldink, Jan4 aut
700a Van Damme, Philip4 aut
710a Umeå universitetb Neurovetenskaper4 org
773t Annals of Neurologyd : John Wiley & Sonsg 89:4, s. 686-697q 89:4<686-697x 0364-5134x 1531-8249
856u https://doi.org/10.1002/ana.26009y Fulltext
856u https://umu.diva-portal.org/smash/get/diva2:1525569/FULLTEXT02.pdfx primaryx Raw objecty fulltext:print
856u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ana.26009
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-179430
8564 8u https://doi.org/10.1002/ana.26009

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy